Sutezolid: Oxazolidinone antibacterial treatment of tuberculosis

Drugs of the Future

Volumn 38, Issue 6, 2013, Pages 387-394

  Lanoix, J P ^a   Nuermberger, E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibiotic; Mycobacterium tuberculosis; PNU 100480; Suterzolid; Thiomorpholine analogue

Indexed keywords

EFAVIRENZ; ISONIAZID; LINEZOLID; RIFAMPICIN; RIFAMYCIN; SUTEZOLID;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG METABOLISM; DRUG SAFETY; DYSGEUSIA; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FIRST PASS EFFECT; HEADACHE; HUMAN; IC 50; LUNG BURDEN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; RADIATION DOSE FRACTIONATION; REVIEW; TREATMENT DURATION;

EID: 84930538823     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.06.1965098     Document Type: Review

References (46)

1. Barbachyn, M.R., Hutchinson, D.K., Brickner, S.J. et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996, 39(3): 680-5. (Pubitemid 26069690)
2. Brickner, S.J., Barbachyn, M.R., Hutchinson, D.K. (Pfizer, Inc.). Substituted oxazine and thiazine oxazolidinone antimicrobials. US 5880118.
3. Barbachyn, M.R., Brickner, S.J., Hutchinson, D.K. (Pfizer, Inc.). Substituted oxazine and thiazine oxazolidinone antimicrobials. EP 0717738, JP 1997502436, US 5688792, WO 1995007271.
4. Brickner, S.J., Nuermberger, E., Stover, C.K. (Pfizer, Inc.). Combination therapy for tuberculosis. CN 102143748, EP 2340022, JP 20122502017, KR 2011063518, US 2011190199, WO 2010026526.
5. World Health Organization. Global tuberculosis report 2012 (in IRIS). Geneva. WHO, 2012.
6. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. Geneva. WHO, 2011.
7. Seung, K.J., Omatayo, D.B., Keshavjee, S., Furin, J.J., Farmer, P.E., Satti, H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS ONE 2009, 4(9): e7186.
8. Gandhi, N.R., Shah, N.S., Andrews, J.R. et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010, 181(1): 80-6.
9. Cohen, J. Infectious disease. Approval of novel TB drug celebrated with restraint. Science 2013, 339(6116): 130.
10. Chaisson, R.E., Nuermberger, E.L. Confronting multidrug-resistant tuberculosis. N Engl J Med 2012, 366(23): 2223-4.
11. Gler, M.T., Skripconoka, V., Sanchez-Garavito, E. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366(23): 2151-60.
12. Brickner, S.J., Hutchinson, D.K., Barbachyn, M.R. et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J Med Chem 1996, 39(3): 673-9.
13. Zurenko, G.E., Yagi, B.H., Schaadt, R.D. et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996, 40(4): 839-45. (Pubitemid 26117523)
14. García-Tapia, A., Rodríguez, J.C., Ruiz, M., Royo, G. Action of fluoroquinolones and linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis. Chemotherapy 2004, 50(5): 211-3. (Pubitemid 39541230)
15. Rodríguez, J.C., Ruiz, M., López, M., Royo, G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002, 20(6): 464-7. (Pubitemid 35379989)
16. Alffenaar, J.W., van der Laan, T., Simons, S. et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011, 55(3): 1287-9.
17. Cynamon, M.H., Klemens, S.P., Sharpe, C.A., Chase, S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999, 43(5): 1189-91. (Pubitemid 29214745)
18. Williams, K.N., Stover, C.K., Zhu, T. et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009, 53(4): 1314-9.
19. Williams, K.N., Brickner, S.J., Stover, C.K. et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009, 180(4): 371-6.
20. Cox, H., Ford, N. Linezolid for the treatment of complicated drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis 2012, 16(4): 447-54.
21. Lee, M., Lee, J., Carroll, M.W. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012, 367(16): 1508-18.
22. Hillemann, D., Rüsch-Gerdes, S., Richter, E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2008, 52(2): 800-1. (Pubitemid 351170872)
23. Dooley, K.E., Obuku, E.A., Durakovic, N. et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: Unclear efficacy or untapped potential? J infect Dis 2013, 207(9): 1352-8.
24. Shaw, K.J., Barbachyn, M.R. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011, 1241: 48-70.
25. De Vito, J., Marra, A., Burak, E., Duffy, E. Anti-tuberculosis activity of radezolid. 50th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 12-15, Boston) 2010, Abst B-2020.
26. File, T., Bagheri, F., Bush, L. A phase 2 study comparing two doses of radezolid to linezolid in adults with uncomplicated skin and skin structure infections (uSSSI). 48th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 25-28, Washington, D.C.) 2008, Abst E-1339.
27. Prokocimer, P., De Anda, C., Fang, E., Mehra, P., Das, A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 Randomized Trial Treatment of Skin and Skin Structure Infections. JAMA 2013, 309(6): 559-69.
28. Leach, K.L., Swaney, S.M., Colca, J.R. et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 2007, 26(3): 393-402. (Pubitemid 46687101)
29. McKee, E.E., Ferguson, M., Bentley, A.T., Marks, T.A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 2006, 50(6): 2042-9. (Pubitemid 43807524)
30. Reddy, V.M., Dubuisson, T., Einck, L. et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2012, 67(5): 1163-6.
31. Converse, P., Lee, J., Williams, K. et al. Activity of PNU-100480 and its major metabolite in whole blood and broth culture models of TB. 5th Int Workshop Clin Pharmacol Tuberculosis Drugs (Sept 8, San Francisco) 2012; viewed on March 22 2013: http://regist2.virology-education.com/2012/5tbpk/docs/ 15-Nuermberger.pdf.
32. Williams, K., Minkowski, A., Amoabeng, O. et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012, 56(6): 3114-20.
33. Louie, A., Brown, D., Files, K., Swift, M., Fikes, S., Drusano, G. Pharmacodynamics of PNU-100480 (U, sutezolid), a new axazolidinone, in combination with its active metabolite in the killing of Mycobacterium tuberculosis (Mtb) in an in vitro hollow fiber infection model (HFIM). 52 nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 9-12, San Francisco) 2012, Abst A-1265.
34. Wallis, R.S., Jakubiec, W.M., Kumar, V. et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 2010, 202(5): 745-51.
35. Zhu, T., Nucci, G., Wallis, R.S. The blood bactericidal activity of PNU-100480 (sutezolid, U-480) and its major active metabolite PNU-101603 (U-603) in patients with pulmonary TB: Insight from PK/PD modeling. 52nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 9-12, San Francisco) 2012, Abst A-1268d.
36. Wallis, R.S., Jakubiec, W., Kumar, V. et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011, 55(2): 567-74.
37. Hilgers, A.R., Smith, D.P., Biermacher, J.J. et al. Predicting oral absorption of drugs: A case study with a novel class of antimicrobial agents. Pharm Res 2003, 20(8): 1149-55. (Pubitemid 36951838)
38. Krueger, S.K., Williams, D.E. Mammalian flavin-containing monooxygenases: Structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005, 106(3): 357-87. (Pubitemid 40726294)
39. Sood, R., Bhadauriya, T., Rao, M. et al. Antimycobacterial activities of oxazolidinones: A review. Infect Disord Drug Targets 2006, 6(4): 343-54. (Pubitemid 44890628)
40. Wallis, R.S., Diacon, A.H., Dawson, R. et al. Safety tolerability and early bactericidal activity in sputum of PNU-100480 (sutezolid) in patients with pulmonary tuberculosis. 19th Int AIDS Conf (July 22-25, Washington, D.C.) 2012, Abst THLBB02.
41. Leach, K.L., Brickner, S.J., Noe, M.C., Miller, P.F. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci 2011, 1222: 49-54.
42. Lee, E., Burger, S., Shah, J. et al. Linezolid-associated toxic optic neuropathy: A report of 2 cases. Clin Infect Dis 2003, 37(10): 1389-91. (Pubitemid 37433638)
43. Bressler, A.M., Zimmer, S.M., Gilmore, J.L., Somani, J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004, 4(8): 528-31. (Pubitemid 39077924)
44. Zivkovic, S.A., Lacomis, D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005, 64(5): 926-7. (Pubitemid 40316349)
45. Wallis, R.S., Palaci, M., Vinhas, S. et al. A whole blood bactericidal assay for tuberculosis. J Infect Dis 2001, 183(8): 1300-3. (Pubitemid 32281574)
46. Wallis, R.S., Jakubiec, W., Mitton-Fry, M. et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207 PA-824, SQ109, and pyrazinamide. PLoS ONE 2012, 7(1): e30479.